NASDAQ:ZLAB
Zai Lab Ltd Stock News
$21.01
+4.44 (+26.80%)
At Close: May 09, 2024
Zai Lab and MacroGenics Enter Into Broad Strategic Collaboration to Develop and Commercialize Preclinical Bispecific Antibodies in Oncology
07:30am, Wednesday, 16'th Jun 2021
SHANGHAI, SAN FRANCISCO and ROCKVILLE, MD, June 16, 2021 (GLOBE NEWSWIRE) -- Zai Lab Limited (NASDAQ: ZLAB; HKEX: 9688), an innovative commercial-stage biopharmaceutical company, and MacroGenics (NASD
Week In Review: Zai Lab Enters $338 Million Agreement To In-License KRAS Inhibitor
11:57pm, Sunday, 06'th Jun 2021
Week In Review: Zai Lab Enters $338 Million Agreement To In-License KRAS Inhibitor
3 Stocks With Solid Balance Sheets for the Value Investor
10:08am, Thursday, 03'rd Jun 2021
Benjamin Graham, the father of value investing, suggested screening the market for stocks that have a current ratio of more than 2 plus more working capital than long-term debt.
Zai Lab Announces First Patient Treated in China in the Registrational Phase 2 TRIDENT-1 Study of Repotrectinib
07:30am, Friday, 28'th May 2021
SHANGHAI and SAN FRANCISCO, May 28, 2021 (GLOBE NEWSWIRE) -- Zai Lab Limited (NASDAQ: ZLAB; HKEX: 9688), an innovative commercial-stage biopharmaceutical company today announced dosing of the first pa
SHANGHAI and SAN FRANCISCO, May 24, 2021 (GLOBE NEWSWIRE) -- Zai Lab Limited (NASDAQ: ZLAB; HKEX: 9688), an innovative commercial-stage biopharmaceutical company, today announced treatment of the firs
Zai Lab Limited (ZLAB) CEO Samantha Du on Q1 2021 Results - Earnings Call Transcript
02:58pm, Monday, 10'th May 2021
Zai Lab Limited (ZLAB) CEO Samantha Du on Q1 2021 Results - Earnings Call Transcript
Zai Lab Announces First Quarter 2021 Financial Results
07:32am, Monday, 10'th May 2021
Company to Host Conference Call and Webcast Today at 8:00 a.m. EDT Company to Host Conference Call and Webcast Today at 8:00 a.m. EDT
Week In Review: Zai Lab Raises $750 Million In Private Placement For In-Licensed/Novel Drugs
04:11am, Monday, 26'th Apr 2021
Week In Review: Zai Lab Raises $750 Million In Private Placement For In-Licensed/Novel Drugs
Zai Lab Announces Closing of Public Offering of American Depositary Shares and Full Exercise of Greenshoe Option
10:49am, Friday, 23'rd Apr 2021
SHANGHAI and SAN FRANCISCO, April 23, 2021 (GLOBE NEWSWIRE) -- Zai Lab Limited (“Zai Lab” or the “Company”) (NASDAQ:ZLAB, HKEX: 9688), an innovative commercial stage biopharmaceutical company,
ZLAB Stock: Over 5% Increase Pre-Market Explanation
09:15am, Wednesday, 21'st Apr 2021
The stock price of Zai Lab Ltd (NASDAQ: ZLAB) increased by over 5% pre-market. This is why it happened.
Zai Lab Announces Pricing of Public Offering of American Depositary Shares and Ordinary Shares
07:40pm, Tuesday, 20'th Apr 2021
SHANGHAI and SAN FRANCISCO, April 20, 2021 (GLOBE NEWSWIRE) -- Zai Lab Limited (“Zai Lab” or the “Company”) (NASDAQ:ZLAB, HKEX: 9688), an innovative commercial stage biopharmaceutical company,
ZLAB Stock: Over 5% Decrease Pre-Market Explanation
09:22am, Tuesday, 20'th Apr 2021
The stock price of Zai Lab Limited (NASDAQ:ZLAB) fell by over 5% pre-market. This is why it happened.
Zai Lab Announces Proposed Public Offering of American Depositary Shares
04:05pm, Monday, 19'th Apr 2021
SHANGHAI and SAN FRANCISCO, April 19, 2021 (GLOBE NEWSWIRE) -- Zai Lab Limited (“Zai Lab” or the “Company”) (NASDAQ:ZLAB, HKEX: 9688), an innovative commercial stage biopharmaceutical company,
Zai Lab Partner Novocure Announces Update on Phase 3 Pivotal LUNAR Trial of Tumor Treating Fields in Non-Small Cell Lung Cancer
07:37am, Tuesday, 13'th Apr 2021
Pre-specified interim analysis concluded with favorable recommendation to continue the LUNAR trial
China NMPA Approves QINLOCK® (Ripretinib) for Treatment of Advanced Gastrointestinal Stromal Tumors (GIST)
04:57am, Wednesday, 31'st Mar 2021
China NMPA approval follows 2020 U.S. FDA approval for the treatment of patients with fourth-line GIST
